Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

March 23, 2023

NASDAQ US Health Care Biotechnology earnings 48 min

Earnings Call Speaker Segments

David Szekeres

executive
#1

Thanks, Lisa. Hello, everyone, and I appreciate you being with us this afternoon. Here with me from Heron are Barry Quart, our Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; and Kimberly Manhard, Executive Vice President of Drug Development. If you're on the conference call, the slides are available through webcast, and you can also get them by visiting the Investor Relations page on our website once today's call wraps up. Before we get started, I want to note that forward-looking statements regarding Heron's future expectations, plans, prospects, corporate strategy and performance will be part of this call, and these count as forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Various important factors, including those covered in our SEC filings, could cause actual results to differ materially from what these forward-looking statements indicate. Also, any forward-looking statements reflect our views only as of the date of this webcast and shouldn't be relied upon as representing our views as of any later date. We specifically disclaim any obligation to update such statements. I'll now hand the call over to Barry.

Barry Quart

executive
#2

Thank you, David. Good afternoon, everyone, and thanks for being here with us today. If anyone is curious about the reason this call falls later in the month than it typically does, the explanation is that we do not currently qualify as an accelerated filer, and we wanted our newly reconstituted Board of Directors to have a chance to become familiar with the company prior to wrapping up the quarter; our fourth quarter was outstanding, and we are clearly very pleased about the significant sales growth for ZYNRELEF during that quarter, as well as the expansion of our CINV business. With this month's launch of APONVIE, which is our fourth commercial product, our portfolio is now complete. ZYNRELEF has gotten off to a slower start in the first quarter because surgeries normally decline seasonally during the opening quarter of every year. Despite that anticipated drop in surgeries, ZYNRELEF is still growing, though not as quickly as it did in the fourth quarter. Management and the Board have been collaborating intensively on a plan to speed up growth for ZYNRELEF and our other products. Experience in the real world with ZYNRELEF keeps demonstrating robust efficacy, in line with what our clinical trials showed, yet customers tell us there are 2 areas where growth could be improved: broadening the label and making it easier to pull the drug product out of the vial. Fixing the narrow label is already underway through our December submission of sNDA #2, which seeks a label covering soft tissue and orthopedic procedures. Should those requested indications be approved, they would essentially encompass all 14 million of our target procedures; at present, the ZYNRELEF kit includes a vented vial spike that we designed to make withdrawing the product as straightforward as possible. An unforeseen complication has arisen from the high turnover of nurses in the post-COVID period. Since ZYNRELEF is viscous, fully withdrawing the product can still require several minutes, and it can take even longer when a nurse does not follow the instructions. That can be frustrating and lead to reduced use of the product. With the broader label anticipated later this year, we want to ensure the product is as user-friendly as we can make it. There will be 2 steps to the optimization. The first step involves finishing development and securing approval for a substantially better custom device built to accelerate product withdrawal; the second step is to keep developing a prefilled syringe. Since customers have told us they would use more ZYNRELEF if it were simpler to remove from the vial, and since the prefilled syringe is still a few years away, we came up with an innovative vial access needle, or VAN, which cuts the withdrawal time from minutes down to roughly 30 seconds. It also encloses the vial so that a non-sterile nurse no longer needs to be involved in withdrawing the drug product. This seamless single person withdrawal was very well received in testing by both customers and noncustomers. We are working hard to secure approval for this device by the middle of next year. As I mentioned, the prefilled syringe is the ideal presentation for ZYNRELEF, and we have spent several years working on it. This technology is something we know well, since SUSTOL comes in a prefilled syringe. That said, ZYNRELEF has turned out to be far more complex and has substantial — which has stretched out the development timeline considerably. The really encouraging part is that we've just gotten past a number of the toughest hurdles and can now move this development project ahead. One more plus is that prefilled syringes for ZYNRELEF ought to also bring down the cost of goods. At this point I'll hand the call over to John.

John Poyhonen

executive
#3

Thanks, Barry. Across our acute care and oncology care franchises, we achieved strong progress in Q4. In my presentation, I'll begin with several updates on key performance metrics for ZYNRELEF, after which I'll give an update on the APONVIE launch, and then close with an update on yet another robust commercial quarter for our oncology care business. First, I'll summarize ZYNRELEF's quarterly results on our lead performance indicators. Historically, Q4 has been the best quarter for the surgical procedures we're currently indicated for. We capitalized on that seasonality, with ZYNRELEF net sales reaching $3.9 million for the quarter — a 44% rise versus the prior quarter and a 362% rise versus the same quarter a year earlier. Demand units in Q4 climbed to 20,765, up 38% versus the prior quarter and up 301% versus the same quarter a year earlier. By the close of Q4, total unique ordering accounts for ZYNRELEF had reached 793, versus 704 at the end of Q3. As of the end of February 2023, total formulary approvals for ZYNRELEF had reached 522, versus 416 approvals as of the end of October 2022. Importantly, we're also seeing momentum with integrated delivery networks, or IDNs, with an updated total of 74 IDNs having placed ZYNRELEF on formulary. Securing IDN support matters greatly for driving therapeutic interchanges with our key accounts — substituting ZYNRELEF for Exparel for indicated procedures going forward. All told, we delivered strong progress in Q4 and are putting key initiatives in place to speed up ZYNRELEF sales within our existing user accounts in 2023. As noted on the previous slide, elective procedures have shown consistent quarterly seasonality. Q4 has consistently been the highest-volume quarter, since patients have met their annual deductibles by that point in the year, plus they have holiday time off to recover and revamp. The line graph on this slide shows that quarterly seasonality using Exparel historical sales from 2018 through 2022, adjusted by removing 2020 results so the direct COVID impact is eliminated. Historically, Q4 has delivered substantial growth versus Q3, only to be followed by a substantial decline in Q1 results. As noted earlier, ZYNRELEF demand units rose 38% in Q4 versus Q3. That works out to an average of 1,597 units per week during the quarter. With 2 weeks left in Q1 2023, the ZYNRELEF weekly average is roughly 1,760 units per week — a 10% gain over the Q4 weekly average. Next, I wanted to update you on a key top-down strategy: targeting integrated delivery networks, or IDNs, to create new system-wide opportunities for Therapeutic Interchange from Exparel to ZYNRELEF for indicated procedures. So far, 74 IDNs have placed ZYNRELEF on their formularies, versus 66 in our last uptake report. Those 74 integrated delivery networks represent more than 1.1 million procedures per year where ZYNRELEF is indicated. And now, when it comes to our IDN formulary expansion, we're covering $149 million in annual Exparel sales, plus we've grown to 17 IDNs that are at different points in considering a switch away from Exparel toward ZYNRELEF. Earlier, we rolled out a new metric designed to gauge the effect we're having with IDNs. Just to reiterate, that performance metric is branded market share — put simply, it's ZYNRELEF units divided by Exparel units plus ZYNRELEF units combined; and to compare how IDNs are doing against the whole market basket, we've added a total market branded share alongside the IDN subcategories. The branded results for the IDN subcategory haven't yet been refreshed to capture all 74 IDNs, including those with formulary approval and the 17 IDNs looking at Therapeutic Interchange, since a lot of those decisions landed right in Q4 or during this quarter. We'll bring those figures up to date to capture every one of our IDN wins when we report next quarter. Broadly speaking, among the 66 IDNs that have formulary approval, we're seeing strong branded market share growth of 9.1%, roughly double what the total market shows. Moving IDNs toward a Therapeutic Interchange evaluation marks a key milestone in speeding up ZYNRELEF's growth. As shown in the table, the 15 IDNs evaluating TI posted a combined 12.5% branded share in Q4, well above the average across the 66 IDNs that have ZYNRELEF on formulary. And lastly, we've given ZYNRELEF's branded market share for the top 5 IDN accounts among those 15 IDNs evaluating Therapeutic Interchange from Exparel to ZYNRELEF. This table illustrates that our branded market share has the potential to climb quite fast, nearing a high approaching 50% for the fourth quarter. Given our current indicated procedures, 50% is close to the ceiling of what we anticipate achieving before an additional label expansion, which we expect in October of this year. We've shown various iterations of this slide before. The version today updates the pricing to reflect WAC price increases that took effect January 1, 2023. Making the switch to ZYNRELEF delivers a cost savings of 23% to 34% on a wholesale acquisition cost basis. Even after Pacira at last offered 340B pricing in the fourth quarter of 2022, ZYNRELEF's 340B pricing still gives 340B accounts savings of 23% to 32% versus Exparel. A number of 340B customers we've talked with have said that Pacira's move on the ZYNRELEF pricing strategy simply leaves them unable to compete effectively on the strength of our clinical and value proposition. And finally, from a reimbursement perspective, ZYNRELEF continues to be far more profitable when treating Medicare patients. In tough financial times, only ZYNRELEF is reimbursed separately, outside the surgical bundle payment and the hospital outpatient setting of care, which makes up roughly 60% of the market opportunity. Given those economic figures, it makes sense that big IDNs keep assessing ZYNRELEF for Therapeutic Interchange along with the procedures it's indicated for, and they're eager to curb how much Exparel gets used. Since we anticipate FDA clearance of our broader indications later in 2025, we'd anticipate far more IDNs shifting toward making that switch. Building steady usage among accounts already ordering is what matters most to us. Our sales team is focused on boosting pull-through and growing the typical order size. Reaching that goal could come from getting more surgeons at every account to use ZYNRELEF, along with more surgical procedures being performed. In Q4, we started putting new flexible resources in place so we'd have extra staff available to in-service surgeons and their teams. We've run pilots with 2 kinds of flexible resources. The hospital implementation team relies on operating room educators to launch new accounts, concentrating on in-services covering every indicated surgical line, which lays a solid foundation going forward. Beyond that, in select territories we've brought in medical device representatives to grow our Orthopedic business through TKA, THA, and foot and ankle surgeries; note that these reps earn compensation solely for the incremental growth they bring in. We're also concentrating on stepping up communication around several ongoing real-world evidence studies involving ZYNRELEF. As an illustration, Dr. Kevin Warner from Covenant Healthcare delivered a poster presentation at orthopaedics today featuring preliminary findings that compare ZYNRELEF against a generic joint cocktail.

John Poyhonen

executive
#4

According to what they found, when ZYNRELEF was included in a multimodal protocol for TKA, there was a substantial decrease in pain as well as morphine consumption across a 24-hour period relative to the joint cocktail. What's more, patients given ZYNRELEF had a length of stay that was more than 24 hours shorter. We think real-world data of this kind is going to shift how practice is done, and we are collaborating with additional health care providers so their data can be shared. Through our work with IDNs, we've achieved meaningful gains in expanding ZYNRELEF branded market share, and we'll keep seeking ways to grow our pipeline and go after therapeutic interchanges with new customers. To wrap up, Barry noted earlier that ZYNRELEF delivers outstanding results for patients, but some customers have told us they'd like withdrawing the drug from the vial to be simpler, and we're committed to making that step better going forward. Now I want to turn the presentation toward APONVIE, the new offering we've developed to prevent post-operative nausea and vomiting, or PONV; our confidence is strong that both APONVIE and the PONV category amount to a substantial opportunity for Heron. Let's start with what it's called. The name APONVIE evokes aprepitant or PONV. When we tested the brand name in market research, health care providers responded very positively, and importantly, it distinguishes this lower dosage version of aprepitant emulsion from CINVANTI, a product for CINV that has proven highly effective and successful. Our focus is on reaching 36 million procedures each year involving patients who face moderate-to-high risk of PONV. Among those, roughly 12 million moderate-to-high-risk individuals currently get no preventive treatment at all. One of our aims is to use the 2020 consensus guidelines to shift that practice, growing the market while tackling one of the post-surgical side effects that worries patients the most. Through market research, we identified a major unmet need in the current landscape — including demand for something easier to use that works faster, which is exactly what APONVIE offers via a quick IV push and 97% receptor occupancy in under 5 minutes. There's also demand for greater efficacy, and aprepitant stands as the top-performing option for preventing PONV, whether used by itself or alongside other treatments. And last, longer-lasting treatment with APONVIE gives PONV prevention for as long as 48 hours. This final unmet need matters especially given the growth in outpatient surgeries and patients being discharged after surgery; in short, APONVIE is clearly differentiated in this market and positioned for success. APONVIE is also the ideal strategic fit for Heron given the synergies with our commercial organization. It begins with tremendous overlaps of accounts we already target for ZYNRELEF; we have established trusted relationships with anesthesia and pharmacy, which is critical for formulary access and usage. Furthermore, roughly 65% of our CINVANTI business comes from the hospital market. The strong relationships we already have with big hospitals and IDNs, plus those positive experiences, ought to give us a running start on getting access and driving use. Now I'd like to walk through a few early plans and highlights for the APONVIE launch. Speeding up formulary access for APONVIE is going to matter more than anything else to our success. A compelling value proposition is where all of this begins. Our offering will include 340B pricing, GPO contracts, and prime vendor discounts across the full wholesaler line. Here's the key point: for three years, APONVIE will stand alone as the only PONV prevention product that gets paid for separately rather than through the surgical bundle for PONV prevention, which is possible because of pass-through status for Medicare patients. Getting early access off the ground will depend heavily on precise targeting, and we plan to begin with accounts that use oral aprepitant, CINVANTI, and ZYNRELEF. In addition, we believe there is an opportunity in leveraging the 2020 consensus PONV guidelines by concentrating on patients at high-to-moderate risk for PONV. We have done this kind of thing before with the NCCN guidelines, which we successfully promoted during the CINVANTI launch, when we expanded the NK market by 35% in year one. I also want to give you an update on some very early commercial momentum for APONVIE: as of March 6, 2023, we completed the first stocking of the distribution channel, including full line and specialty distributors, and a number of those distributors have already placed APONVIE reorders. Last week, we shared the news that CMS gave APONVIE pass-through status lasting three years, beginning on April 1, 2023, with the code C9145. The early response from customers has us really excited. During the March 7 investor conference, we told everyone about the initial formulary approval and the very first end-user sale for APONVIE. Today I'm able to report that a 9 hospital system has become our first IDN to approve it for its formulary, and the medical executive committee approved adding it to the formulary today, with that taking effect in April. Obviously, it's still quite early, but we're eager to share more information as the year progresses. At this point, I want to shift gears and discuss how our oncology care franchise performed in the fourth quarter. During Q4, our oncology care team accomplished a great deal, expanding net sales in our CINV business by 32% compared with the equivalent quarter a year earlier. Getting our CINV franchise back to growth after generic arbitrages involving both products is something we take real pride in, and we expect it to remain a valuable, highly profitable franchise for many years ahead. Across the entire year, net sales for our CINV franchise reached $97.5 million, which represents a 17% gain versus the previous year. We continue to feel good about where our CINV products are headed, thanks to reimbursement momentum that has been building over the last twelve months. The table makes clear that CINVANTI and SUSTOL both sit in a strong reimbursement spot relative to rival offerings; on top of that, generic fosaprepitant no longer gets separate reimbursement in the hospital outpatient setting as of January 1, 2022, which keeps strengthening the case for CINVANTI's value. Under new CMS rules that took effect January 1, 2023, reimbursed or 340B accounts are now paid at ASP plus 6%, up from the earlier ASP minus 22%, handing those customers a financial boost. Our thinking is that a substantial share of CINVANTI demand sales already sits within 340B accounts. This fresh opening should let us push unit sales up by an even bigger margin during the current year. And finally, since we're now producing CINVANTI at scale in line with what's sitting in the distribution channel's inventory, gross margin has climbed from about 50% and is moving in the direction of 75%. Looking at all of 2023, we expect net sales for the CINV franchise to come in somewhere from $99 million to $103 million. That wraps up what I had prepared, so I'll give the call back to Barry at this point.

Barry Quart

executive
#5

Appreciate that, John. We'll close out the prepared remarks by turning to the slide covering our financials. Heron ended December 31, 2022 with $84.9 million across cash, cash equivalents and short-term investments. Net cash burned by operating activities during the three months ended December 31, 2022 totaled $37.5 million, and that figure reflects a payment of about $10 million tied to polymer. Strip out that polymer payment and our underlying burn lands at roughly $27 million, while the complete effect of the approximately 34% headcount reduction carried out last year will continue flowing through both this year and next. Fourth quarter 2022 R&D expense declined to $11.1 million, compared with $28.9 million in the fourth quarter of '21 and $20.5 million in the prior quarter. We're collaborating with every one of our manufacturers to reduce outside costs during the coming years while sales continue to grow. For Q2 and Q3, we'd anticipate cash burn to be in the teens. After spending the past several days alongside our newly reconstituted board, I can confidently state that they are fully committed to lengthening our cash runway and enhancing our valuation. Following a review of the data and time spent with our sales force, the new Board members remain enthusiastic about our products. Slides 21 through 24 include critical safety information for ZYNRELEF and APONVIE. Those slides can be found on our website. With that, we're ready to take your questions. Operator?

Josh Schimmer

analyst
#6

To start, a brief question about the accounts receivable line. It seems that went up from one quarter to the next. What's behind that?

Barry Quart

executive
#7

What's behind it is simply a bit of timing around payments, which, as you're aware, all of it ultimately gets paid, plus higher sales throughout the year.

Josh Schimmer

analyst
#8

All right. So I'm attempting to square what was said regarding the challenges posed by the label and the delivery device that isn't optimal; given how tough this launch has clearly been so far, which struck me as somewhat at odds with the extremely upbeat adoption figures John gave for the IDNs; therefore I'm trying to determine whether there are any real near-term opportunities for growth during this year. Why keep pressing ahead with commercialization before you've gotten the broader label and the simpler device product profile sorted out?

Barry Quart

executive
#9

Sure, I'll hand it over to John. Still, at the outset, I'd say the product keeps expanding for us; we're achieving substantial progress. What we've pinpointed, clearly, is one area — actually 2 areas — that are going to matter for speeding up growth beyond what we're currently experiencing. Naturally, though, we intend to keep spreading the word and building the product. As John mentioned, there's a chance to share real-world data that's currently being produced now that the product is on the market; that's something we've discussed throughout the past year. Nearly every major site ran its own studies before beginning to use the product, purely due to earlier encounters with other offerings in this space, and that was one of the aspects of the launch that consumed the most time; consequently, a wealth of data is about to emerge that will keep bolstering uptake of the product from now until later in this year, when the expanded label arrives and, with luck, soon afterward we enhance the product by making it simpler to use; so clearly this is an ongoing process, yet adoption keeps growing for us. And clearly, we intend to drive that forward with maximum effort. John, anything you'd like to add?

John Poyhonen

executive
#10

Sure. So when we consider IDNs, like Barry said, the fact that all of them are conducting internal evaluations, and that requires a certain amount of time. That's a key point, and it shows up in some of the growth we've observed. But the outcomes they're producing were generally — really have been outstanding; that's the reason we keep bringing on additional IDNs. We brought on several very large ones right at the close of last year. And those accounts are extremely keen and enthusiastic about replacing their Exparel business with ZYNRELEF, given the clinical profile and what we offer on the value proposition side. Now, as Barry noted, there are certain obstacles when it comes to preparation. One method we're pursuing to address that involves using medical device representatives. They're present in the operating room, particularly for orthopedics, each and every day. So they're able to assist and ensure the product is on the tray at the moment the surgeon requires it. So that's a near-term fix that can truly help us operate very effectively. The other factor we consider significant is that we anticipate a label expansion in October, which is not very far off. And since accounts and IDNs have been achieving excellent results, they'll consider bringing on extra service lines once that label expansion arrives. So I believe we can keep growing. I think the second quarter, simply due to seasonality, has always been more robust than the first quarter, and we would definitely anticipate that moving forward.

Josh Schimmer

analyst
#11

Then, John, you gave us a few positive early adoption figures for APONVIE. Conversely, you also gave positive adoption figures for ZYNRELEF, and I believe most investors would say that one has so far been a pretty big letdown. So given that your remarks previously didn't exactly signal the kind of launch investors were hoping for, why should we trust what you're saying about APONVIE?

John Poyhonen

executive
#12

Yeah. That's a completely reasonable question. What I'd say is that APONVIE, in my view, is a whole different situation. To start with, our indication for PONV prevention is broad, meaning we aren't restricted by which surgical procedures it can be used in. Another point, Josh, on the ease-of-use side, the training obstacles aren't the same; it's simply a 30 seconds IV push; hospitals do this kind of thing daily. That means reps don't need to stay in the accounts to confirm the training is — gets done, taking the product out of the vial. So although there are definitely some quite positive early results we're seeing, our belief is that this product is very different in terms of ease of use, and uptake will be very rapid once we get moving and secure formulary access.

Brandon Folkes

analyst
#13

Nice work on the progress. First off, could you perhaps go into detail about a few of the choices available to you for strengthening your cash runway? I'm aware you mentioned that, and that you're kind of collaborating with the Board on it. So could you maybe expand on that? Then, in that same vein, what's the right way to think about R&D from here, given that the sNDA for the ZYNRELEF label expansion has now been submitted, plus the prefilled syringe and VAN you brought up today?

Barry Quart

executive
#14

Sure. Thank you, Brandon. So regarding your second question, I'll take that one first. When it comes to R&D expense ahead, we keep doing everything we can to keep R&D in check throughout this year, even with what we're doing to try to advance the prefilled syringe. That's a fairly modest outlay next to conducting large-scale clinical trials; we'll pursue it as cost-effectively as we can. And we've already made substantial moves to bring down our R&D expense, as I believe the figures we reported for the fourth quarter reflect, and we'll keep examining ways to lower burn, in R&D and in other areas too. I'm unable to share specifics right now. The Board remains in what you might call the data gathering phase, cooperating very closely with management, and we will definitely give updates once they're ready.

Brandon Folkes

analyst
#15

Great, and perhaps just a single follow-up. When it comes to that 10% growth, the volume growth, are there any factors pushing or pulling on revenue we ought to keep in mind for Q1 — basically, why might revenue or might not track that closely?

Barry Quart

executive
#16

Yes, excellent question; and without a doubt, during the first quarter on a year-over-year basis, you've got what we present regarding ZYNRELEF's seasonality, plus ordering patterns, and the combination of the 2 vial sizes could be different. So I'm not sure whether John or David have anything specific they can contribute regarding Brandon's question.

John Poyhonen

executive
#17

Brandon, were you asking about ZYNRELEF, specifically?

Brandon Folkes

analyst
#18

Right. Yeah.

John Poyhonen

executive
#19

Yeah. So when you take a look at it, I believe Barry has it right. What we've observed is that more general surgery procedures are coming into the fold, and that's quite encouraging. At the outset, our launch leaned far more toward orthopedics; because of that, there's a greater proportion of the 200-milligram SKU, and that SKU carries a lower cost value. And then, I think, looking at certain figures from a historical perspective, over time, from the angle of demand, you can see that. Additionally, as we pick up business in 340B accounts, the net selling price will come down somewhat. So there's going to be a degree of sensitivity that we'll keep monitoring. I think the last element is that we implemented our first price increase in — taking effect January 1. So a very small buy-in happened at the close of the previous quarter, likely around a week or 2. So those are the things that would shape the actual results for Q1.

Serge Belanger

analyst
#20

We have a few questions. To start, Barry, could you describe what's happening with fiscal volumes generally? As was said earlier, your competitor has faced a headwind because things haven't fully bounced back. So I'm just wondering what you've observed during this year up to now. I realize the first quarter tends to be sluggish, though normally once March arrives, things settle for us; so I'm curious what you're seeing regarding those strengths?

Barry Quart

executive
#21

Right. And I believe John is able to weigh in — offer a bit more detail. Without a doubt, January is extremely sluggish; and February brought decent improvement and March was robust, producing growth across the quarter as a whole. John, would you like to add anything further?

John Poyhonen

executive
#22

Yeah. I believe that when you take a look at that slide we presented, it's still the case that seasonality for the product applies. On the whole, our indicated procedures for last year were lower by 4.1 to 4.6% against 2021 volume. During the first quarter of this year so far, they're tracking quite similarly to where they stood in 2022, Serge; so — though we're still at an early point. When the actual unit volume becomes available, the claims data has a tendency to lag somewhat. So that's something for us to examine and give an update on when we hold our next earnings call.

Serge Belanger

analyst
#23

All right. Second, you mentioned your intentions to enhance how the ZYNRELEF product is presented. I'm just wondering, what would the regulatory consequences be in this case? From the FDA's perspective, what would need to happen for these presentation improvements to be cleared?

Barry Quart

executive
#24

It would be exactly the same as creating any other device, much like the Luer Lock applicator included in our kit. You'd need to carry out standard manufacturing steps, demonstrating sterility, showing how radiation is employed to sterilize the device, and how it's packaged. You assemble all those materials, and an outside manufacturer handles all of it — that contract manufacturer produces a great many devices of this kind and has deep expertise in this work. So they supply all the necessary information for the submission. After that, it comes down to 2 possible routes that could be pursued: submitting a 510(K) as a device, and also submitting a pre-approval supplement, so the product can be packaged in the kit. Typically, the 510(K) moves more quickly. As a result, we're right now looking at ways to determine whether we might speed things up by taking that route. There are certain technical problems tied to doing so that we'll need to resolve together with the FDA. Yet regardless of which route is chosen, it essentially involves developing the device and proving you can write proper usage instructions. There aren't many significant obstacles. Even though the device is fairly novel in the way we've engineered it, a vial access needle is, in its basic idea, very ordinary. And the instruction or training needed to operate it would truly be tiny.

Kelly Shi

analyst
#25

This is Claire, filling in for Kelly. My initial question concerns ZYNRELEF. Could you provide additional detail regarding your approach to driving greater adoption among those accounts already placing orders regularly? In your view, what will mark the turning point for ZYNRELEF's sales trajectory? Additionally, might you offer a bit more insight into how the EU launch is progressing?

Barry Quart

executive
#26

Yes. John, would you like to handle the first portion?

John Poyhonen

executive
#27

Absolutely. So what we're concentrating on at this moment is our current customers, ensuring our sales reps can truly get the most surgeons possible using a product. Often, in these early evaluations that are happening, they might begin with perhaps 2 or 3 orthopedic surgeons, while a practice could have 5 to 8. So we aim to genuinely capitalize on the favorable outcomes from that first trial phase and grow to those remaining surgeons. Another item on our agenda is broadening the procedures we perform, so if we begin with total — somebody might be able to mute, there's quite a bit of noise in the background there. So the additional thing we're doing is seeking to broaden the surgical procedures. So if somebody begins in TKA, clearly we want to move into hips; we're also then wanting to broaden inside an account into other surgical lines. So if things are going well in orthopedics, what can we accomplish in general surgery and bariatrics? What can we accomplish in C-section, where are extra areas where we can grow the business; and we are starting to see solid traction from taking that approach. A few of the flexible resources we're bringing in, such as the medical device reps, are assisting greatly, too, since they possess such a strong relationship with orthopedic surgeons, there may be some where our relationships aren't strong and are tougher to convert. And we've already witnessed growth coming from accounts by utilizing that. So there's a range of truly strategies we're employing there. But I believe most of it is simply ensuring we leave no stone unturned within accounts that already have existing business.

Barry Quart

executive
#28

Yeah. As far as the EU situation goes, there's honestly nothing new to share. Finding a partner there has proven difficult again and again, and launching that product on our own isn't something we plan to do — it's a costly undertaking, and using our cash for that right now is definitely not something we'd want.

Analyst

analyst
#29

Understood. That is quite useful; and regarding the APONVIE launch, you have mentioned the initial indicators you have observed from the launch 2 weeks ago. And perhaps could you provide us with additional detail on the APONVIE ramp-up? And for instance, what are the extra sales force you might require to support the APONVIE ramp-up? And in what way should we anticipate the cost increase tied to that?

Barry Quart

executive
#30

Yes, John, would you like to take that?

John Poyhonen

executive
#31

Naturally. When it comes to how quickly sales will build, the real deciding factor is how fast we can secure formulary approval; that's one of our top priorities at the moment. Just like with all our products, no guidance is offered while a launch is underway. So there isn't anything further we can share right now. Our intention is to keep giving updates on how things are going as we move forward, but we're just 2 weeks in. On the extra expense side, we're relying on the ZYNRELEF sales team we already have. They reach precisely the same audience. Our people are already in front of anesthesiologists, pharmacy, and surgeons. And thankfully, there's enormous overlap between the target accounts we're pursuing, particularly the oral aprepitant accounts and the ZYNRELEF accounts we hold. So compared with our overall commercial spend, only a very small percentage of the total budget goes incrementally toward launching APONVIE.

Barry Quart

executive
#32

Thanks a lot, and I appreciate all of you being with us on today's call; we're eager to continue sharing updates with you going forward.

Operator

operator
#33

Everyone, that brings us to the end of this session. We appreciate your joining us, and you're free to hang up at this point. Farewell.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.